Skip to main content
MEDIPOSTCO.,LTD. logo

MEDIPOSTCO.,LTD. — Investor Relations & Filings

Ticker · 078160 ISIN · KR7078160009 KO Manufacturing
Open in API
Filings indexed 366 across all filing types
Latest filing 2023-03-02 Proxy Solicitation & In…
Country KR South Korea
Listing KO 078160

About MEDIPOSTCO.,LTD.

https://en.medi-post.co.kr/

MEDIPOST is a biotechnology company specializing in the research, development, and commercialization of stem cell therapeutics and regenerative medicine. The company focuses on addressing unmet medical needs for incurable diseases through its proprietary stem cell platform technology. Its core operations include a cord blood banking service and the development of allogeneic stem cell therapies. Key commercialized products include CARTISTEM®, a treatment for knee cartilage defects and osteoarthritis, and PNEUMOSTEM®, a preventive therapy for bronchopulmonary dysplasia in premature infants. The company's clinical pipeline features next-generation injectable treatments for conditions such as osteoarthritis and diabetic nephropathy.

Recent filings

Filing Released Lang Actions
[기재정정]의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Proxy Solicitation of Voting Rights) and is a formal filing submitted to the Financial Supervisory Service (FSS) in South Korea. It contains detailed information regarding the upcoming Annual General Meeting (AGM), including the purpose of the meeting, agenda items (such as approval of financial statements, director appointments, etc.), and instructions for shareholders to exercise their voting rights via proxy. This document is a standard Proxy Solicitation statement used to request shareholder votes for an AGM.
2023-03-02 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea (Proxy Solicitation & Information Statement). It contains information regarding the upcoming Annual General Meeting (AGM), including the purpose of the meeting, details on the proxy solicitation, and financial statements (balance sheet, income statement) provided as reference material for shareholders to vote on. Since it is a formal solicitation document for a shareholder meeting, it falls under the Proxy Solicitation & Information Statement category.
2023-02-24 Korean
[기재정정]의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Proxy Solicitation Reference Document) and is filed by Medipost Co., Ltd. It contains information regarding the upcoming Annual General Meeting (AGM), including the purpose of the meeting, voting procedures, and proxy solicitation details. While it contains financial statements, these are provided as part of the proxy materials for shareholder approval, not as a standalone annual report. Therefore, it is classified as a Proxy Solicitation & Information Statement.
2023-02-24 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Notice of Annual General Meeting' (주주총회소집공고) for Medi-Post Co., Ltd. It contains the meeting agenda, details on voting procedures, director activity reports, and financial summaries. This type of document is specifically designed to provide shareholders with the necessary information to vote on company matters at the AGM, which falls under the category of Proxy Solicitation & Information Statement.
2023-02-24 Korean
[기재정정]매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) system regarding a 'Correction Report' (정정신고) for a previous disclosure about a 30% change in revenue or profit/loss structure. This type of filing is a standard regulatory requirement for listed companies in Korea to update financial data before the final audit is completed. Since it is a specific regulatory disclosure regarding financial performance updates rather than a full annual report or a simple announcement of a report, it falls under the 'Regulatory Filings' category. FY 2022
2023-02-20 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from MediPost regarding a significant change in revenue or profit/loss structure (30% or more). It provides a summary table of financial performance (revenue, operating profit, net income) comparing the current fiscal year to the previous one, along with the reasons for the change. This is a standard Korean regulatory disclosure (DART filing) for material financial changes, which falls under the 'Earnings Release' category as it provides the initial announcement of financial results highlights before the full audit is finalized. FY 2022
2023-02-06 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.